Unicycive Therapeutics, Inc.
NCM: UNCYLive Quote
📈 ZcoreAI Score
Our AI model analyzes Unicycive Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get UNCY Z-Score →About Unicycive Therapeutics, Inc.
Healthcare
Biotechnology
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
📊 Fundamental Analysis
Unicycive Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -141.1%, which indicates that capital utilization is currently under pressure.
At a current price of $6.63, UNCY currently sits at the 40th percentile of its 52-week range (Range: $3.71 - $11.00).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$167.33M
Trailing P/E
--
Forward P/E
0.77
Beta (5Y)
1.80
52W High
$11.00
52W Low
$3.71
Avg Volume
568K
Day High
Day Low